Summary
Thermo Fisher Scientific Inc. reported solid financial results for the second quarter and first six months of 2012, demonstrating revenue growth driven by strategic acquisitions and organic expansion across its key segments. The company's revenue increased year-over-year, reflecting the positive impact of recent acquisitions like Phadia and Dionex, alongside continued demand for its products and services in Analytical Technologies, Specialty Diagnostics, and Laboratory Products and Services. Despite increased interest expenses related to financing these acquisitions, the company managed to improve operating income and margins, showcasing operational efficiencies and integration success. Management anticipates continued weakness in academic and government markets but remains optimistic about overall growth prospects, supported by a strong cash flow from operations and a well-established credit facility. The company also announced a significant upcoming acquisition of One Lambda, signaling continued strategic expansion and commitment to strengthening its market position in specialty diagnostics.
Financial Highlights
56 data points| Revenue | $3.11B |
| Cost of Revenue | $1.50B |
| Gross Profit | $1.32B |
| R&D Expenses | $94.20M |
| SG&A Expenses | $835.00M |
| Operating Expenses | $2.74B |
| Operating Income | $367.80M |
| Interest Expense | $57.40M |
| Net Income | $233.80M |
| EPS (Basic) | $0.64 |
| EPS (Diluted) | $0.63 |
| Shares Outstanding (Basic) | 367.00M |
| Shares Outstanding (Diluted) | 369.20M |
Key Highlights
- 1Consolidated revenues for the second quarter of 2012 increased by 9% to $3.11 billion compared to the prior year period, driven by acquisitions and existing business growth.
- 2Operating income for the second quarter of 2012 rose by 39% to $368 million, with a corresponding increase in operating margin to 11.8% from 9.3% in the prior year.
- 3The company recorded a significant charge of $51 million related to the estimated loss on the planned divestiture of its laboratory workstations business.
- 4Acquisitions, including Phadia and Dionex, continue to be a major driver of revenue growth, particularly in the Specialty Diagnostics and Analytical Technologies segments.
- 5Net cash provided by operating activities for the first six months of 2012 was $899.5 million, an increase from $693.3 million in the same period of 2011.
- 6The company has established new revolving credit facilities totaling up to $2.0 billion, demonstrating a strong liquidity position.
- 7A definitive agreement to acquire One Lambda for approximately $866 million was announced post-quarter end, highlighting continued strategic investment in specialty diagnostics.